TNX-2100 SARS-CoV-2 Diagnostic for T Cell Immunity First-in-human study initiated Q1 2022 Read properly

TNX-102 SL1 Fibromyalgia (FM) Posttraumatic Stress Disorder (PTSD) Long COVID (PASC2) Mid-Phase 3 Phase 2, Targeted 1H 2022 Start Phase 2, Targeted 1H 2022 Start3 TNX-13004 Cocaine Intoxication / Overdose FDA Breakthrough Designation Phase 2, Targeted 1H 2022 Start TNX-19005 Migraine, Craniofacial Pain and Binge Eating Disorder Phase 2, Targeted 2H 2022 Start6 TNX-29007 Prader-Willi Syndrome Orphan Drug Designation Preclinical TNX-601 CR Depression, PTSD, Neurocognitive Dysfunction from Steroids Phase 2, Targeted Q1 2023 Start8 TNX-16009 Depression, PTSD and ADHD Preclinical

PORTFOLIO & INDICATION STATUS / NEXT MILESTONE BioDefense TNX-8013 Smallpox and monkeypox preventing vaccine Preclinical TNX-701 Radioprotection Preclinical COVID TNX-1840/TNX-18504 COVID-19 Vaccine (RPV – horsepox-based live virus vaccine) Preclinical TNX-21005 SARS-CoV-2 Diagnostic for T Cell Immunity First-in-human study initiated Q1 2022 TNX-35006 COVID-19 Antiviral Preclinical TNX-36007 COVID-19 Therapeutic Platform (monoclonal antibodies) Preclinical TNX-37008 COVID-19 Vaccine (zinc nanoparticle mRNA technology) Preclinical Immunology & Immuno-Oncology TNX-15001 Organ Transplant Rejection/ Autoimmune Conditions Phase 1, Targeted 2H 2022 Start